NO20063720L - Antidiabetiske oksazolidiendioner og tiazolidiendioner - Google Patents

Antidiabetiske oksazolidiendioner og tiazolidiendioner

Info

Publication number
NO20063720L
NO20063720L NO20063720A NO20063720A NO20063720L NO 20063720 L NO20063720 L NO 20063720L NO 20063720 A NO20063720 A NO 20063720A NO 20063720 A NO20063720 A NO 20063720A NO 20063720 L NO20063720 L NO 20063720L
Authority
NO
Norway
Prior art keywords
thiazolidinediones
dione
diabetes
type
oxazolidinediones
Prior art date
Application number
NO20063720A
Other languages
English (en)
Norwegian (no)
Inventor
Peter T Meinke
Guo Q Shi
James F Dropinski
Young Zhang
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO20063720L publication Critical patent/NO20063720L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/44Two oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/62Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems having two or more ring systems containing condensed 1,3-oxazole rings
    • C07D263/64Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems having two or more ring systems containing condensed 1,3-oxazole rings linked in positions 2 and 2' by chains containing six-membered aromatic rings or ring systems containing such rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20063720A 2004-01-20 2006-08-18 Antidiabetiske oksazolidiendioner og tiazolidiendioner NO20063720L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53763004P 2004-01-20 2004-01-20
PCT/US2005/001344 WO2005070905A1 (en) 2004-01-20 2005-01-18 Antidiabetic oxazolidinediones and thiazolidinediones

Publications (1)

Publication Number Publication Date
NO20063720L true NO20063720L (no) 2006-10-09

Family

ID=34807112

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063720A NO20063720L (no) 2004-01-20 2006-08-18 Antidiabetiske oksazolidiendioner og tiazolidiendioner

Country Status (22)

Country Link
US (1) US20070173434A1 (zh)
EP (1) EP1709014B1 (zh)
JP (1) JP2007518803A (zh)
KR (1) KR20060128921A (zh)
CN (1) CN100451008C (zh)
AT (1) ATE363475T1 (zh)
AU (1) AU2005206540B2 (zh)
BR (1) BRPI0506919A (zh)
CA (1) CA2553405A1 (zh)
CY (1) CY1106757T1 (zh)
DE (1) DE602005001265T2 (zh)
DK (1) DK1709014T3 (zh)
ES (1) ES2287908T3 (zh)
IL (1) IL176878A0 (zh)
MX (1) MXPA06008190A (zh)
NO (1) NO20063720L (zh)
NZ (1) NZ548556A (zh)
PL (1) PL1709014T3 (zh)
PT (1) PT1709014E (zh)
RU (1) RU2355682C2 (zh)
WO (1) WO2005070905A1 (zh)
ZA (1) ZA200605512B (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006138328A1 (en) * 2005-06-14 2006-12-28 Merck & Co., Inc. Process for the production of antidiabetic oxazolidinediones
AU2006269503A1 (en) 2005-07-06 2007-01-18 Merck & Co., Inc. Antidiabetic oxazolidinediones and thiazolidinediones
CA2612984A1 (en) * 2005-07-20 2007-02-15 Merck & Co., Inc. Antidiabetic oxazolidinediones and thiazolidinediones
WO2008096769A1 (ja) * 2007-02-08 2008-08-14 Daiichi Sankyo Company, Limited 置換されたセルコスポラミド誘導体を含有する医薬
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
AU2019282727A1 (en) 2018-06-06 2020-11-26 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease
MX2020013567A (es) 2018-06-14 2021-05-27 Poxel Tableta recubierta con pelicula que comprende un derivado de triazina para su uso en el tratamiento de la diabetes.
CN111892569A (zh) * 2019-05-05 2020-11-06 石家庄圣泰化工有限公司 4,4’-联-1,3-二氧戊环-2,2’-二酮的合成方法
CN112898265A (zh) * 2019-11-18 2021-06-04 石家庄圣泰化工有限公司 4,4’-联-1,3-二氧戊环-2,2’-二酮的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07138258A (ja) * 1993-11-16 1995-05-30 Taiho Yakuhin Kogyo Kk チアゾリジンジオン誘導体又はその塩
US6114526A (en) * 1996-07-01 2000-09-05 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
WO1999032465A1 (en) * 1997-12-19 1999-07-01 Merck & Co., Inc. Arylthiazolidinedione derivatives
WO2003018135A1 (en) * 2001-08-24 2003-03-06 Wyeth Holdings Corporation Method of using 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase

Also Published As

Publication number Publication date
BRPI0506919A (pt) 2007-06-05
IL176878A0 (en) 2006-10-31
RU2355682C2 (ru) 2009-05-20
PT1709014E (pt) 2007-08-13
DK1709014T3 (da) 2007-09-10
AU2005206540B2 (en) 2009-01-08
KR20060128921A (ko) 2006-12-14
US20070173434A1 (en) 2007-07-26
PL1709014T3 (pl) 2007-10-31
ES2287908T3 (es) 2007-12-16
NZ548556A (en) 2009-03-31
JP2007518803A (ja) 2007-07-12
WO2005070905A1 (en) 2005-08-04
MXPA06008190A (es) 2006-08-31
DE602005001265D1 (de) 2007-07-12
EP1709014A1 (en) 2006-10-11
AU2005206540A1 (en) 2005-08-04
RU2006129930A (ru) 2008-02-27
CA2553405A1 (en) 2005-08-04
ZA200605512B (en) 2007-11-28
CN100451008C (zh) 2009-01-14
CN1910163A (zh) 2007-02-07
ATE363475T1 (de) 2007-06-15
EP1709014B1 (en) 2007-05-30
DE602005001265T2 (de) 2008-01-31
CY1106757T1 (el) 2012-05-23

Similar Documents

Publication Publication Date Title
NO20063720L (no) Antidiabetiske oksazolidiendioner og tiazolidiendioner
NO20075000L (no) Kondenserte aromatiske forbindelser med anti-diabetisk aktivitet
WO2006014262A3 (en) Indoles having anti-diabetic activity
WO2004019869A3 (en) Indoles having anti-diabetic activity
NO20051546L (no) Indoler med anti-diabetisk aktivitet
WO2004066963A3 (en) N-cyclohexylaminocarbonyl benzenesulfonamide derivatives
PE20060415A1 (es) Compuestos heteroaril- y fenilsulfamoilo sustituidos
MA27317A1 (fr) Inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase 1 utiles pour le traitement du diabete, de l'obesite et de la dyslipidemie
ATE472531T1 (de) Sulfonylverbindungen als hemmer von 11-beta- hydroxysteroiddehydrogenase-1
ATE345128T1 (de) Modulatoren der peroxisom-proliferator- aktivierten rezeptoren (ppar)
NO20010628L (no) Substituerte oksazol- og thiazolderivater som hPPAR <gamma> og hPPAR <alfa> aktivatorer
NO20054396D0 (no) 3-metyl-2-(3-(2-fenyl-oksazol-4-ylmetoksy)-cykloheksankarbonyl-amino)-smorsyrederivater og lignende forbindelser som PPAR-modulatorer til behandling av type 2 diabetes og aterosklerose
NO20081821L (no) Forbindelser for behandling av metabolske forstyrrelser
BR0213253A (pt) Composto, uso do mesmo, composição farmacêutica, e, métodos para o tratamento de condições mediadas por receptores nucleares e de diabetes tipo i, diabetes tipo ii, dislipidemia, sìndrome x (incluindo a sìndrome metabólica, i.e. tolerância prejudicada à glicose, resistência á insulina, hipertrigliceridemia e/ou ou obesidade), doenças cardiovasculares (incluindo aterosclerose) ou hipercolesteremia
DK1789403T3 (da) N-(phenyl-oxazol-4ylmethoxymethyl)-cyclohexyl-ravsyreamid derivater og beslægtede forbindelser som PPAR-ligander (peroxisom-proliferator-aktiverede receptorer) til behandling af hyperlipidæmi og diabetes
ATE327983T1 (de) Thia- und oxazole und deren verwendung als ppars- aktivatoren
ATE382043T1 (de) Sulfonamid-derivate als ppar-modulatoren
BR0211414A (pt) Composto, uso do mesmo, composição farmacêutica, e, métodos para o tratamento e/ou prevenção de condições mediadas pelos receptores nucleares e de diabetes tipo i, diabetes tipo ii, tolerância à glicose, resistência à insulina ou obesidade prejudicadas
WO2007018956A3 (en) Antidiabetic oxazolidinediones and thiazolidinediones
ATE515494T1 (de) Neue verbindungen, deren herstellung und verwendung
WO2006022954A3 (en) Benzoureas having anti-diabetic activity
WO2004037776A3 (en) Novel compounds and their use as prar-modulators
DE602005024539D1 (de) Neue verbindungen, ihre herstellung und verwendung
DE602005022585D1 (de) Phenoxyessigsäurederivate als ppar-agonisten
NO20074738L (no) Aktivator for peroksisom-proliferator som aktiverer reseptor delta

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application